

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Trasciatti et al.  
App. No : 10/530,108  
Filed : April 1, 2005  
For : PROCEDURE FOR THE LARGE-SCALE  
T-LYMPHOCYTES CULTURE IN A  
HOMOGENEOUS SYSTEM  
Examiner : Jalla, Sanjoo  
Art Unit : 1644

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 3, 2006

(Date)


Marina L. Gordey, Reg. No. 52,950

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing 4 references.
  - (X) Enclosing 4 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

  
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Trasciatti et al.  
App. No : 10/530,108  
Filed : April 1, 2005  
For : PROCEDURE FOR THE LARGE-  
SCALE T-LYMPHOCYTES  
CULTURE IN A HOMOGENEOUS  
SYSTEM  
Examiner : Jalla, Sanjoo  
Art Unit : 1644

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 4 references to be considered by the Examiner. Also enclosed are 4 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.


This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 3, 2006

By:   
Marina L. Gordey  
Registration No. 52,950  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)  SHEET 1 OF 1	Application No.	10/530,108
	Filing Date	April 1, 2005
	First Named Inventor	Trasciatti et al.
	Art Unit	1644
	Examiner	Jalla, Sanjoo
	Attorney Docket No.	NOTAR4.001APC

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	1	O'CONNOR, R. et al. (1991) "Growth factor requirements of childhood acute t-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro" Blood 77:1634-1645.	
	2	CESANO, A. et al. (1992) "Two unique human leukemic t-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms" In Vitro Cell. Dev. Biol. 18A:648-656.	
	3	CESANO, A. et al. (1996) "Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic t-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets" Blood 87:393-403.	
	4	CESANO, A. et al. (1996) "Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic t-cell line (tal-104) in immunocompetent mice bearing syngeneic leukemia" Cancer Research 56:444-4452.	

2212991:vr  
121505

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.